Media Gallery

FEATURES

Florida Trend– 2020

A side of seaweed?

Researchers with the University of Florida’s College of Pharmacy say seaweed has anti-inflammatory properties that might ward off colon cancer and other inflammation-related digestive diseases.

Smithsonian Marine Station – 2020

Decrypting Defenses

Smithsonian research into cyanobacteria’s powerful chemical compounds yields benefits for humans as well as reef habitats.

University of florida on Youtube – 2019

Every Day is Game Day Video

Hendrik Luesch, Ph.D., and his research lab are featured in the University of Florida’s 2019 TV commercial which aired during Gator sporting events.

UF Health’s The Post – 2008

Under the Sea

Forget visions of frothy, bubbling beakers — Hendrik Luesch, Ph.D., calls the ocean his laboratory, where marine organisms may hold the key to curing the world’s worst diseases.

COVER ART GALLERY

ACS Infectious Diseases Cover July 2022

2022 – Dr. Hendrik Luesch

ACS Infectious Diseases

Apratoxin S4 in action against SARS-CoV-2: This host-directed antiviral shuts off spike protein production and trafficking (top) and prevents double membrane vesicle formation and assembly of progeny virions (bottom).

ACS Chemical Neuroscience

2020 – Dr. Hendrik Luesch

ACS Chemical Neuroscience

Surfing across the blood-brain barrier with a purpose and a splash: The marine natural product and potent class I HDAC inhibitor largazole has activity against glioblastoma cells and induces neuroprotective and antiproliferative functional responses in the brain through modulation of gene expression of entire networks underlying CNS diseases.

Organic Letters Journal

2019 – Dr. Hendrik Luesch

Organic Letters

The cover image illustrates the multidisciplinary research that linked a natural product discovered from the depicted marine cyanobacteria to GPCR modulation. The portrayed peptide, amantamide, was isolated, synthesized, and characterized as a selective CXCR7 agonist. Molecular modeling of amantamide provides the starting point for rational optimization.

CHEMBIOCHEM journal cover

2018 – Dr. Hendrik Luesch

ChemBioChem

The cover feature picture shows Ahp-cyclodepsipeptides, the producing marine cyanobacterium overgrowing a coral, and the compounds’ anticancer effects. These cyclodepsipeptides inhibit human neutrophil elastase and, as a consequence, the migration of invasive breast cancer cells through the modulation of gene expression and proteolytic processing of membrane proteins.

Current Drug Targets

2012 – Dr. Hendrik Luesch

Current Drug Targets

Small molecules that modulate histone acetylation by targeting key enzymes mediating this posttranslational modification – histone acetyltransferases and histone deacetylases – are validated chemotherapeutic agents for the treatment of cancer. Secondary metabolites from various biological sources target this epigenetic modification through distinct mechanisms of enzyme regulation by utilizing a diverse array of pharmacophores. We review the discovery of these compounds and discuss their modes of inhibition together with their downstream biological effects.

Concepts-Frontispiece-2010_200h

2010 – Dr. Hendrik Luesch

Chemistry – A European Journal

Natural products are secondary metabolites that confer survival advantages to the producing organism. Many require activation before they exert their biological effects, perhaps as part of the organism's self‐resistance strategy or to aid targeted delivery. In this Concept article Luesch and Kwan outline several examples of “Weapons in Disguise”, natural products that use protecting group chemistry or intricate chemical cascades for activation beyond simple “prodrug” paradigms.

The Journal of Pharmacology and Experimental Therapeutics

2010 – Dr. Hendrik Luesch

The Journal of Pharmacology and Experimental Therapeutics

The Luesch lab previously described the bioassay-guided isolation, structure determination, synthesis, and target identification of largazole, a marine-derived antiproliferative natural product that is a prodrug that releases the most potent natural inhibitor of class I histone deacetylases (HDACs), validated targets for cancer therapy. The cover highlights structure-activity studies using biochemical and molecular docking approaches. The article describes the characterization of the anticancer activity of largazole using in vitro and in vivo cancer models, including comparative transcriptomics, pharmacology, biochemical validation, stability, and efficacy studies.

Natural Products Reports

2010 – Dr. Hendrik Luesch

Natural Product Reports

Hendrik Luesch’s discovery of largazole and its producing cyanobacterium are featured in this annual Marine Natural Products review and on the journal cover, respectively.


Molecular Biosystems

2006 – Dr. Hendrik Luesch

Molecular BioSystems

Genome-scale analysis has been extended from gene expression profiling to parallel cell-based functional profiling, allowing the characterization of gene function and small molecule actions in yeast and in mammalian cells.

Nature Chemical Bio journal cover

2006 – Dr. Hendrik Luesch

Nature Chemical Biology

This is the first report that uses an unbiased functional genomics approach in cancer cells to study the mode of action of a potent cyanobacterial cytotoxin and also visualizes “apratoxin A in action” in zebrafish.

This lab is managed by Hendrik Luesch